Elicio Therapeutics, Inc.
ELTXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Elicio Therapeutics, Inc. focuses on Biotechnology services and products. Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Valued at $61.8M, ELTX is a micro-cap name in its sector. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Market Cap
$61.8M
Beta
1.86
P/E (TTM)
—
P/E (Fwd)
-1.09
EPS (TTM)
$-2.16
EPS (Fwd)
$-2.17
ROE
-774.6%
ROA
-77.9%
Cash
$23.5M
Total Debt
$14.1M
Free CF
-$22.3M
52W Change
-79.5%
Annual Financials
Cash vs Debt
Where ELTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ELTX finished 68.28% below its 150-day moving average ($8.04) and 68.44% below its 200-day moving average ($8.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELTX overbought or oversold?
At the September 3, 2026 close, ELTX's RSI(14) was 17.4, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $23.5M in cash comfortably exceeding the $14.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$22.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -774.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, ELTX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Elicio Therapeutics, Inc. and its sector.